CYP2C19基因多态性对药物代谢影响的研究进展

彭净; 刘卫

doi:10.3969/j.issn.1006-0111.2015.06.008

CYP2C19基因多态性对药物代谢影响的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.008

彭净¹,
刘卫^2,

1.
解放军88医院, 山东泰安 271000;济宁医学院附属医院, 山东济宁 272000
2.
解放军88医院, 山东泰安 271000

基金项目: 山东省药学会奥赛康中青年临床药师资助项目(No.sdpa-ask-2013-02)

Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism

PENG Jing¹,
LIU Wei^2
,

1.
No. 88 Hospital of PLA, Taian 271000, China;Affiliated Hospital of Jining Medical University, Ji'ning 272000, China
2.
No. 88 Hospital of PLA, Taian 271000, China

摘要: 药物代谢和相互作用的差异与CYP的单核苷酸基因多态性有关。综述CYP2C19基因多态性对质子泵抑制剂、抗真菌药伏立康唑、抗血小板药氯吡格雷的代谢和药物相互作用的影响,以期为个体化用药提供参考。
- CYP2C19 /
- 基因多态性 /
- 质子泵抑制剂 /
- 伏立康唑 /
- 氯吡格雷
Abstract: Drug metabolism and drug-drug interactions were associated with the single nucleotide polymorphisms of CYP. The relationship between CYP2C19 polymorphisms and metabolism as well as interactions of proton pump inhibitors, voriconazole and clopidogrel were reviewed to provide evidence for personalized medication.
- CYP2C19 /
- polymorphism /
- proton pump inhibitor /
- voriconazole /
- clopidogrel

[1]	吴敏良,吴晓虹,陈枢青. 细胞色素P4502C19 在中国汉族人群不同组织中的分布差异研究[J] .中国药学杂志,2005,40(3):215-218.
[2]	Bertilsson L,Lou YC, Du YU,et al.Pronounced difference between native Chinese and Swedish populations in the polymorphichydroxylation of debrisoquin and S-mephenytoin[J]. Clin Pharmacol Ther, 1992,51(4):388-397.
[3]	Blaisdell J,Mohrenweiser H,Jackson J,et al.Identification and functional characterization of new potentially defective alleles of human CYP2C19[J]. Pharmacogenetics, 2002,12(9):703-711.
[4]	Sim SC, Risinger C, Dahl ML, et al.A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants[J] . Clin Pharmacol Ther,2006,79(1):103-113.
[5]	Xie HG,Huang SL,Xu ZH,et al.Evidence for the effect of gender on activity of S-mephenytoin in a Chinese population[J]. Pharmacogenetics, 1997,7(2):115-119.
[6]	Wedlund PJ,Aslanian WS,McAllister CB,et al.Mephenytoin hydroxylation deficiency in caucasians: frequency of a new oxidative drug metabolism polymorphism [J]. Clin Pharmacol Ther,1984,36(6):773-780.
[7]	Jacquehnes SM, PhamlJ DB, John WF.Determination of CYP2C19 phenotype in black Americans wit homeprazole: correlation with genotype [J]. Clin Pharmacol Ther,1996,60(2):138-144.
[8]	Zhang YX, Wei SJ, Yang XY,et al. Effects of genetic polymorphisms of CYP2C192/3 and MDR1 C3435T on the pharmacokinetics of lansoprazole in healthy Chinese subjects[J]. Int J Clin Pharmacol Ther, 2014,52(10):850-855.
[9]	姜英杰,李瑜元, 聂玉强, 等. 雷贝拉唑根除幽门螺杆菌疗效及其与CYP2C19 基因多态性的关系[J]. 广州医学院学报, 2004, 32(3): 22-25.
[10]	Sezgin O,Barlas IO,Uçbilek E,et al.Modified sequential Helicobacter pylori eradication therapy using high dose omeprazole and amoxicillin in the initial phase in the extensive metaboliser Turkish patients for CYP2C19 polymorphism is ineffective[J].Acta Gastroenterol Belg,2014,77(1):3-7.
[11]	Lee JY,Kim N,Kim MS,et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance[J]. Dig Dis Sci,2014,59(6):1235-1243.
[12]	John J,Lima,Jason EL,et al.Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children[J]. Pediatry,2013,163(3):686-691.[13] Varenhorst C,James S, Erlinge D, et al.Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not rasugrel in aspirin-treated patients with coronary artery disease[J]. Eur Heart J,2009,30(14):1744-1752.
[13]	Arima Y, Hokimoto S, Akasaka T, et al. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina[J].J Cardiol,2015,65(6):494-500.
[14]	谢婧,杨莉萍,刘瑶,等.CYP2C19*17基因对氯吡格雷临床疗效影响的Meta分析[J]. 中国药房,2012,23(28):2618-2621.
[15]	Crepeau AZ, Moseley BD, Wirrell EC.Specific safety and tolerability considerations in the use of anticonvulsant medications in children[J].Drug Health Patient Saf,2012,4: 39-54.
[16]	Kouga T, Shimbo H, Iai M,et al. Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome[J]. Brain Dev, 2015,37(2):243-249.
[17]	de Leon J.The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19[J].Clin Psychopharm,2007,27(3):241-245.
[18]	王瓅珏,唐惠林,段京莉. CYP2C19基因多态性对伏立康唑药代动力学影响的系统评价[J]. 中国临床药理学杂志,2011,29(8):607-611.
[19]	Zonios D,Yamazaki H,Murayama N,et al.Voriconazole metabolism, toxicity and the effect of cytochrome P450 2C19 genotype [J].J Infect Dis,2014,209(12):1941-1948.
[20]	Choi CI,Bae JW,Lee YJ,et al.Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics[J]. J Clin Psychopharmacol, 2014,34(1):139-142.[22] Nastasi-Catanese JA,Padilla-Gutiérrez JR,Valle Y, et al.Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response[J]. Genet Mol Res,2013,12(4):4413-4421.
[21]	Sibbing D,Morath T,Stegherr J,et al.Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel[J]. Thromb Haemost,2009,101(4):714-719.
[22]	Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor[J].Arch Intern Med, 2010,170(8):704-710.[25] 曲彩红,黎小妍. 伏立康唑与奥美拉唑可能的不良相互作用致肌病及肝功能恶化[J]. 药物不良反应杂志,2011,13(6): 374-377.
[23]	Kim DY,Park HJ,Lee YJ.Factors affecting voriconazole plasma concentrations in patients with invasive fungal infections[J]. Int J Clin Pharmacol Ther,2014,52(3):209-216.
[24]	Simon T, Steg PG, Gilard M, et al.Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P4502C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French registry of acute st-elevation and non-st-elevation myocardial infarction (FAST-MI) registry[J]. Circulation,2011,123(5):474-482.
[25]	Furuta T,Iwaki T,Umemura K. Influences of different proton pump inhibitors on the antiplatelet function of clopidogrel in relation to CYP2C19 genotypes[J] . Br J Clin Pharmacol, 2010, 70(3):383-392.
[26]	Collet JP, Hulot JS, Anzaha G, et al. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (clopidogrel and response variability investigation study 2) [J].JACC Cardiovasc Interv,2011,4(4):392-402.
[27]	Wallentin L,James S,Storey RF,et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial[J].Lancet,2010,376(9749):1320-1328.
[28]	Mega JL,Close SL,Wiviott SD,et al.Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes[J]. Circulation,2009, 119(9):2553-2560.
[29]	Erlinge D,James S,Duvvuru S,et al.Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease[J].Thromb Haemost,2014,111(5):943-950.

[1]	万立志, 王境焓, 吴春蓉, 李玲. 基于代谢组学技术的烟酰胺协同两性霉素B抑制白念珠菌的作用机制研究 . 药学实践与服务, 2026, 44(1): 20-25. doi: 10.12206/j.issn.2097-2024.202307034
[2]	华俊杰, 朱敏, 张鹰楠, 卢光照, 张翮. 氟马西尼舌下喷雾剂在比格犬体内的药动学研究 . 药学实践与服务, 2026, 44(): 1-4. doi: 10.12206/j.issn.2097-2024.202503042
[3]	徐展飞, 李利, 佟向阳, 赵雪超. 汉防己甲素片对绝经后骨质疏松症患者首次唑来膦酸治疗后炎性细胞因子及急性期反应的影响 . 药学实践与服务, 2026, 44(4): 216-220. doi: 10.12206/j.issn.2097-2024.202508039
[4]	王立峰, 阮芳, 虞慧华, 陆松伟, 杨云云. 1例SCN2A基因突变致大田原综合征患儿的药学监护 . 药学实践与服务, 2026, 44(5): 272-274. doi: 10.12206/j.issn.2097-2024.202405033
[5]	孟盼盼, 宋慕格, 杨世超, 陈克明, 杨中铎, 马慧萍. 基于Keap1/Nrf2/HO-1信号通路研究利舒康胶囊对高原缺氧小鼠学习记忆障碍的改善作用 . 药学实践与服务, 2026, 44(1): 26-31, 52. doi: 10.12206/j.issn.2097-2024.202303006
[6]	刘志丽, 吴相雷, 胡云英, 王慧, 鲍蕾蕾. 22例免疫检查点抑制剂致免疫相关性肺炎病例分析 . 药学实践与服务, 2026, 44(): 1-4. doi: 10.12206/j.issn.2097-2024.202512023
[7]	黄文辉, 陈秀芬, 陈建明, 洪雅娜, 蔡静静, 陈锦珊. 钠-葡萄糖协同转运蛋白2抑制剂相关非高血糖性酮症酸中毒的影响因素分析及预测模型建立 . 药学实践与服务, 2026, 44(5): 247-252. doi: 10.12206/j.issn.2097-2024.202403056
[8]	邓晓霞, 田泾, 苏健芬. 钠−葡萄糖协同转运蛋白2的基因组学研究进展及其抑制剂的临床应用 . 药学实践与服务, 2026, 44(5): 228-232. doi: 10.12206/j.issn.2097-2024.202302006
[9]	桂明珠, 李静, 李志玲. 儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2026, 44(2): 76-79, 107. doi: 10.12206/j.issn.2097-2024.202402020
[10]	杨瑾冬, 房振西, 聂成洋, 陈瑞兵, 李卿, 张磊. 丹参及其近缘物种的叶绿体基因组分析 . 药学实践与服务, 2025, 43(6): 275-282. doi: 10.12206/j.issn.2097-2024.202504023
[11]	冯婷婷, 张景翔, 王彦, 许维恒, 张俊平. ANXA3基因及蛋白的研究进展 . 药学实践与服务, 2025, 43(2): 47-50, 74. doi: 10.12206/j.issn.2097-2024.202309023
[12]	于翔, 贾培培, 李欣颖, 杨君君, 郭高峰, 陆连芳. M2型巨噬细胞外泌体喷剂对压力性损伤的疗效及作用机制 . 药学实践与服务, 2025, 43(9): 436-442. doi: 10.12206/j.issn.2097-2024.202503066
[13]	赵全公, 王国坤, 徐志云. 虾青素通过激活Nrf2/HO-1通路抑制瓣膜间质细胞钙化 . 药学实践与服务, 2025, 43(6): 283-287. doi: 10.12206/j.issn.2097-2024.202412057
[14]	施乔, 韩贵焱, 张俊腾, 刘娜. 新型Hsp90抑制剂的设计合成及其抗真菌和抗肿瘤活性研究 . 药学实践与服务, 2025, 43(3): 124-135. doi: 10.12206/j.issn.2097-2024.202501019
[15]	魏莱, 董国强. SARS-CoV-2主蛋白酶抑制剂和降解剂研究进展 . 药学实践与服务, 2025, 43(6): 259-269, 297. doi: 10.12206/j.issn.2097-2024.202503064
[16]	姚瑞阳, 于海征, 李耀盺, 张磊. 丹参FBXL 基因家族的鉴定和表达模式分析 . 药学实践与服务, 2024, 42(11): 461-470. doi: 10.12206/j.issn.2097-2024.202407034
[17]	杨凤艳, 张月, 陈恩贤, 缪雪蓉, 魏凯. 瑞马唑仑临床应用研究进展 . 药学实践与服务, 2024, 42(9): 365-374. doi: 10.12206/j.issn.2097-2024.202405026
[18]	白学鑫, 陈玉平, 盛春泉, 武善超. 具核梭杆菌小分子抑制剂的筛选及其抗结直肠癌活性研究 . 药学实践与服务, 2024, 42(12): 503-507. doi: 10.12206/j.issn.2097-2024.202405009
[19]	刘汝雄, 杨万镇, 涂杰, 盛春泉. 铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075
[20]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(12): 512-519. doi: 10.12206/j.issn.2097-2024.202401050

点击查看大图

计量

文章访问数: 5982
HTML全文浏览量: 882
PDF下载量: 279
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

CYP2C19基因多态性对药物代谢影响的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.008

Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism

计量

CYP2C19基因多态性对药物代谢影响的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.008

1. 解放军88医院, 山东泰安 271000;济宁医学院附属医院, 山东济宁 272000

2. 解放军88医院, 山东泰安 271000

English Abstract

Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism

1. No. 88 Hospital of PLA, Taian 271000, China;Affiliated Hospital of Jining Medical University, Ji'ning 272000, China

2. No. 88 Hospital of PLA, Taian 271000, China

全文HTML

目录

留言板

CYP2C19基因多态性对药物代谢影响的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.008

Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism

计量

出版历程

CYP2C19基因多态性对药物代谢影响的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.008

1. 解放军88医院, 山东 泰安 271000;济宁医学院附属医院, 山东 济宁 272000 2. 解放军88医院, 山东 泰安 271000

English Abstract

Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism

1. No. 88 Hospital of PLA, Taian 271000, China;Affiliated Hospital of Jining Medical University, Ji'ning 272000, China 2. No. 88 Hospital of PLA, Taian 271000, China

全文HTML

目录

1. 解放军88医院, 山东泰安 271000;济宁医学院附属医院, 山东济宁 272000

2. 解放军88医院, 山东泰安 271000

1. No. 88 Hospital of PLA, Taian 271000, China;Affiliated Hospital of Jining Medical University, Ji'ning 272000, China

2. No. 88 Hospital of PLA, Taian 271000, China